P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

Autor: Sylvain Choquet, Andrew Clark, Cécile Renard, Ben Uttenthal, Sridhar Chaganti, Ralf Ulrich Trappe, Patrizia Comoli, Xinyuan Duan, Baodong Xing, Charley Wu, Laurence Gamelin, Jan-Henrik Terwey, Anke Friedetzky, Daan Dierickx

Publikováno v: HemaSphere, Vol 7, p e8073255 (2023)

Externí odkaz: https://doaj.org/article/aa027855236c4b1ea54bea970adf8954

Supplemental Tables and Figures from Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Autor: Scott D. Patterson, Roger Sidhu, Andre S. Jung, Jan-Henrik Terwey, Reija Koukakis, Hua Yu, Pei He, Eric Van Cutsem, Laslo Roman, Tudor E. Ciuleanu, Gregory Wilson, Andrew H. Strickland, Cornelis J.A. Punt, Florian Lordick, Emily Chan, Thierry André, Yevhen Hotko, Michel Ducreux, Alberto F. Sobrero, Andrés Cervantes, Timothy J. Price, Kelly S. Oliner, Marc Peeters

Contains: Table S1. RAS and BRAF Mutation Status Table S2. Objective Response Rate in Patients with Mutated RAS Table S3. Depth of Response and Early Tumor Response in Wild-type KRAS Exon 2 Patients Figure S1. Disposition of patients in the study and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a270e11af1fd12d264083118e64d68d8
https://doi.org/10.1158/1078-0432.22460478

Demographics and treatment outcomes in patients with EBV+ PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses

Autor: Sylvain Choquet, Sridhar Chaganti, Ben Uttenthal, Patrizia Comoli, Ralf Ulrich Trappe, Anke Friedetzky, Baodong Xing, Xiaoming Li, Tobias Boy Polak, Laurence Gamelin, Jan-Henrik Terwey, Daan Dierickx

Publikováno v: Journal of Clinical Oncology. 40:7530-7530

7530 Background: Patients undergoing allogeneic hematopoietic cell transplant (HCT) or solid organ transplant (SOT) are at risk of developing Epstein–Barr virus driven post-transplant lymphoproliferative disorder (EBV+ PTLD), a rare hematologic mal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a33c10cd1b01fdbbf0597b6000e2409a
https://doi.org/10.1200/jco.2022.40.16_suppl.7530

Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL

Autor: Johan Vansteenkiste, Laura Belton, Michael Hedenus, Jan-Henrik Terwey, Enrique Hernandez, Robert Pirker

Purpose Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when initiated at Hb ≤10 g/dL (the threshold specified in the summary of prescribing characteristics). We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf5c25012222800bdd02cfdef8a0e6c
https://lirias.kuleuven.be/handle/123456789/531793

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

Autor: Pilar García-Alfonso, Pavel Fabian, Etienne Rouleau, Jörg Trojan, Jan-Henrik Terwey, Giuseppe Aprile, George Kafatos, Giovanna De Maglio, J. Han van Krieken, Gerald Downey, Laurent Mineur, Aliki Taylor, Jiří Tomášek

Publikováno v: PLoS ONE
PLoS One, 10, 10
PLoS One, 10
PLoS ONE, Vol 10, Iss 10, p e0140717 (2015)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Contains fulltext : 152566.PDF (Publisher’s version ) (Open Access) BACKGROUND: From 2008-2013, the European indication for panitumumab required that patients' tumor KRAS exon 2 mutation status was known prior to starting treatment. To evaluate phy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a0eaefc06dfd636f35fbb59aac710ee
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/152566